Titre:
  • An ongoing European organization for research and treatment of cancer crossover trial comparing single-agent paclitaxel and doxorubicin as first- and second-line treatment of advanced breast cancer.
Auteur:Piccart-Gebhart, Martine; Bruning, Peter; Gamucci, T; Klijn, J G; Roy, J A; Awada, Ahmad; Kusenda, Zlatko; Van Vreckem, A; Paridaens, R.
Informations sur la publication:Seminars in oncology, 23, 5 Suppl 11, page (11-15)
Statut de publication:Publié, 1996-10
Sujet CREF:Sciences bio-médicales et agricoles
MeSH keywords:Adenocarcinoma -- drug therapy
Adult
Aged
Antibiotics, Antineoplastic -- administration & dosage
Antibiotics, Antineoplastic -- adverse effects
Antibiotics, Antineoplastic -- therapeutic use
Antineoplastic Agents, Phytogenic -- administration & dosage
Antineoplastic Agents, Phytogenic -- adverse effects
Antineoplastic Agents, Phytogenic -- therapeutic use
Breast Neoplasms -- drug therapy
Cross-Over Studies
Disease Progression
Doxorubicin -- administration & dosage
Doxorubicin -- adverse effects
Doxorubicin -- therapeutic use
Europe
Female
Heart Failure -- chemically induced
Humans
Infusions, Intravenous
Injections, Intravenous
Middle Aged
Neutropenia -- chemically induced
Paclitaxel -- administration & dosage
Paclitaxel -- adverse effects
Paclitaxel -- therapeutic use
Prospective Studies
Remission Induction
Note générale:Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Langue:Anglais
Identificateurs:urn:issn:0093-7754
info:pmid/8893893